Enacts the "cannabis supply chain integrity and anti-inversion act"; prohibits any act or omission involving illicit cannabis; provides penalties for such cannabis inversion.
Impact
The bill introduces significant amendments to the existing cannabis law, specifically targeting those who engage in or facilitate cannabis inversion. It outlines clear definitions of illicit cannabis and establishes penalties for violations, including civil penalties that may be three times the retail value of the illicit cannabis involved. Additionally, it requires labs and registrants to maintain accurate records that demonstrate the lawful sourcing of cannabis products, placing the burden of proof on them to prove the legality of their inventory in cases of dispute.
Summary
S08951, also known as the "Cannabis Supply Chain Integrity and Anti-Inversion Act," aims to bolster the integrity of New York's regulated cannabis market by defining and prohibiting cannabis inversion, which involves the introduction of illicit cannabis into the legal supply chain. The bill emphasizes the necessity for transparency, traceability, and lawful sourcing of cannabis products sold to consumers. By addressing cannabis inversion, lawmakers seek to protect consumer health, maintain public trust in the regulated market, and secure tax revenues for the state. The legislation seeks to bolster the accountability of individuals and laboratories involved in the cannabis industry.
Contention
While supporters argue that S08951 is essential for curbing illegal cannabis activities and ensuring the integrity of the market, detractors may raise concerns over the stringent penalties and compliance requirements it imposes. The whistleblower protection clause aims to encourage reporting of violations without fear of retaliation, which could raise issues of trust within industry stakeholders who might be wary of the repercussions of reporting infractions. Thus, while the bill seeks to protect public health and order within the cannabis market, it may also create tension between regulatory authorities and cannabis industry participants as they navigate the new legal landscape.
Same As
Enacts the "cannabis supply chain integrity and anti-inversion act"; prohibits any act or omission involving illicit cannabis; provides penalties for such cannabis inversion.
Enacts the "cannabis supply chain integrity and anti-inversion act"; prohibits any act or omission involving illicit cannabis; provides penalties for such cannabis inversion.
Prohibits the cultivation, processing, distribution and sale of edible cannabis products, flavored cannabis vape cartridges and other flavored cannabis products; prohibits the use of food-related names in the labeling or packaging of cannabis products; prohibits the use of food-related names in the advertisement of cannabis products.
Medical cannabis combination business plant canopy increase to cultivate cannabis sold as medical cannabis flower or medical cannabinoid products provision
Plant canopy that a medical cannabis combination business may use to cultivate cannabis that will be sold as medical cannabis flower or medical cannabinoid products increased.